CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENSE AGREEMENTLicense Agreement • November 7th, 2022 • Avalo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This License Agreement (this “Agreement”), dated the 29th day of July, 2022 (the “Effective Date”), is by and between Apollo AP43 Limited, a company incorporated under the laws of England and Wales (“Licensee”), and Avalo Therapeutics, Inc., a Delaware corporation (“Avalo”). Avalo and Licensee may each be referred to herein individually as a “Party” and collectively as the “Parties.”
PURCHASE AGREEMENT BY AND AMONG AVALO THERAPEUTICS, INC., AND ES THERAPEUTICS, LLC DATED AS OF NOVEMBER 4, 2022Purchase Agreement • November 7th, 2022 • Avalo Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This PURCHASE AGREEMENT, dated as of November 4, 2022 (this “Agreement”), is made and entered into by and among Avalo Therapeutics, Inc., a Delaware corporation (“Seller”), and ES Therapeutics, LLC, a Delaware limited liability company (the “Buyer”). Terms with initial capitalized letters not otherwise defined in this Agreement have the meaning ascribed to them in Section 8.1.
